- Investing.com
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company’s lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Metrics to compare | GRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGRTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.1x | −4.5x | −0.5x | |
PEG Ratio | 0.00 | 0.01 | 0.00 | |
Price/Book | 0.0x | 2.7x | 2.6x | |
Price / LTM Sales | - | 150.6x | 3.3x | |
Upside (Analyst Target) | - | 187.1% | 43.4% | |
Fair Value Upside | Unlock | 2.9% | 7.1% | Unlock |